JPRN-UMIN000002795
Completed
Phase 2
Phase II study of erlotinib in previously treated non-small cell lung cancer (NSCLC) with wild type EGFR(NEJ006/TCOG0903) - Erlotonib in pre-treated NSCLC with wild type EGFR
orth East Japan Study Group /The Tokyo Cooperative Oncology Group0 sites43 target enrollmentNovember 25, 2009
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Pre-treated non-small cell lung cancer with wild type EGFR and occurred in never or light smoker
- Sponsor
- orth East Japan Study Group /The Tokyo Cooperative Oncology Group
- Enrollment
- 43
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\)Presence of active interstitial pneumonia, radiation pneumonia, pneumoconiosis, or drug induced pneumonia 2\)Uncontrolled pleural effusion, ascites, or pericardial effusion 3\)Presence of infection that necessitates treatments with intravenous antibiotics 4\)History of HER\-related drug treatment 5\)T790M mutation 6\)Symptomatic eye disease 7\)Pregnant patients 8\)Symptomatic brain metastases 9\)Other active malignancies 10\)Poorly controlled diabetes mellitus 11\)Severe and uncontrolled complication 12\)Current smoker 13\)Evaluated to be ineligible by a physician for other reasons
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 2
Phase II study of Erlotinib in previously treated advanced non-small cell lung cancer patients with carcinomatous meningitison-small cell lung cancerJPRN-UMIN000007020ung Oncology Group in Kyushu, Japan (LOGIK)32
Completed
Not Applicable
PhaseII study of erlotinib in previously treated non-small cell lung cancer (NSCLC) with wild type EGFRPre-treated non-small cell lung cancer with wild type EGFR and occurred in never or light smokerJPRN-UMIN000005491Hiroshima citizens hospital Department of Medical Oncology40
Completed
Phase 2
Phase II study of Erlotinib for previously treated advanced or recurrent non-small-cell lung cancer with EGFR wild type and KRAS wild typeadvanced or recurrent non-small-cell lung cancerJPRN-UMIN000008398Gunma Uninersity Hospital30
Completed
Phase 2
A Phase II Study of Erlotinib for previously treated Non-small cell Lung Cancer Patients with Epidermal Growth Factor Receptor Mutatioon-small cell lung cancerJPRN-UMIN000002716Central Japan Lung Study Group (CJLSG)29
Completed
Phase 2
A Phase II Study of Erlotinib for previously treated Non-small cell Lung Cancer Patients without Epidermal Growth Factor Receptor Mutatioon-small cell lung cancerJPRN-UMIN000002692Central Japan Lung Study Group (CJLSG)54